TrialJournal of the European Academy of Dermatology and Venereology : JEADV2025

Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study.

C Tziotzios et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.